



(51) International Patent Classification:

A61P 35/00 (2006.01) C07K 16/32 (2006.01)
A61P 35/02 (2006.01) C07K 16/40 (2006.01)
C07K 14/71 (2006.01)

(21) International Application Number:

PCT/US2021/047574

(22) International Filing Date:

25 August 2021 (25.08.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/070,782 26 August 2020 (26.08.2020) US

(71) Applicant: MARENGO THERAPEUTICS, INC.
[US/US]; 840 Memorial Drive, 4th Floor, Cambridge, MA 02139 (US).

(72) Inventors: LOEW, Andreas; c/o Marengo Therapeutics, Inc., 840 Memorial Drive, 4th Floor, Cambridge, MA 02139 (US). KATRAGADDA, Madan; c/o Marengo Therapeutics, Inc., 840 Memorial Drive, 4th Floor, Cambridge, MA 02139 (US). TIFFANY, Andrea; c/o Marengo Therapeutics, Inc., 840 Memorial Drive, 4th Floor, Cambridge, MA 02139 (US).

tics, Inc., 840 Memorial Drive, 4th Floor, Cambridge, MA 02139 (US).

(74) Agent: UM, Moonkyoung; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: ANTIBODY MOLECULES THAT BIND TO NKP30 AND USES THEREOF

Activation of NK92 cells by NK p30 Ab




FIG. 2

(57) Abstract: Antibody molecules that specifically bind to NKp30 are disclosed. The anti-NKp30 antibody molecules can be used to treat, prevent and/or diagnose cancerous, autoimmune or infectious conditions and disorders.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

07 April 2022 (07.04.2022)